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Cardiovascular disease is a common cause of death in patients with chronic obstructive pulmonary disease (COPD) and is a key target for
improving outcomes. However, there are concerns that patients with COPD may not have enjoyed the same mortality reductions from acute
myocardial infarction (AMI) in recent decades as the general population. This has raised questions about differences in presentation, manage-
ment and outcomes in COPDpatients compared to non-COPD patients. The evidence points to an increased risk of death after AMI in patients
with COPD, but it is unclear to what extent this is attributable to COPD itself or to modifiable factors including under-treatment with
guideline-recommended interventions and drugs. We review the evidence for differences between COPD and non-COPD patients in terms
of the presentation of AMI, its treatment, and outcomes both in hospital and in the longer term.
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Background
Recent decades have seen substantial reductions in the incidence of
acute myocardial infarction (AMI) and its mortality.1,2 Much of
the decrease in incidence has been attributable to a decrease
in ST-elevation myocardial infarction (STEMI). Rates of non-ST ele-
vation myocardial infarction (NSTEMI) have not decreased and may
be increasing perhaps due to population ageing or clinical aware-
ness.3 Patients with NSTEMI tend to be older and have more co-
morbidities than patients with STEMI, increasing their risk of death
in the longer term.4 Much of the decrease in AMI mortality has been
attributed to improvements in care, but it is not clear if this has been
optimized for all patient groups.5 Some high-risk groups have re-
ceived particular attention and in diabetes, for example, ischaemic
presentations may be atypical and thresholds for investigation and
treatment are set at a lower level compared with non-diabetic pa-
tients.6 However, other groups have received less attention and
chronic obstructive pulmonary disease (COPD), in particular, has
been under-studied in patients with AMI despite it being common,
affecting 1.5% of the European population, although the true
prevalence may be as high as 10% as many patients remain undiag-
nosed.7 In the developed world, the most important risk factor for
COPD is tobacco smoking; other risk factors include increased age,
indoor and outdoor pollution, poor nutrition, and low socio-
economic status.8
Chronic obstructive pulmonary disease is associated with an
increased risk of many other diseases, which are thought to be
due, in part, to ‘spill over’ of inflammation in the lung to the sys-
temic circulation9 (Figure 1). Cardiovascular disease is perhaps
the most common co-morbidity and people with COPD, particu-
larly in younger age groups, are at increased risk of AMI, inde-
pendent of smoking status.10,11 Inflammation, endothelial
dysfunction, and increased arterial stiffness, in addition to shared
risk factors, are all thought to contribute to cardiovascular risk in
COPD.12 Most people with COPD do not die from respiratory
diseases,13 with cardiovascular disease being a major cause, ac-
counting for 30% of all deaths.14
This article will review contemporary literature on how COPD
affects the presentation, management, and outcomes of AMI and
how these may be interrelated.
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Presentation of acute myocardial
infarction
The prevalence of previously diagnosed COPD among patients pre-
senting to hospital with AMI has been estimated as 10–17%.15–18
The true prevalence, including patients with undiagnosed COPD,
may be significantly higher. Several studies have reported that patients
with COPD are less likely to present with typical chest pain than pa-
tients without COPD, and are more likely to present with breathless-
ness, atypical chest pain, and palpitations.15–17 They are also more
likely than patients without COPD to present with NSTEMI than STE-
MI and to have lower diagnostic biomarker levels, including troponin
and creatine kinase.18–21 In one study, COPD has been associated
with late presentation .12 h after onset of symptoms.21
Recognition and management
of acute myocardial infarction
One possible consequence of the differences in presentation of AMI
in COPD is that its recognition is delayed or missed altogether.
Around 8% of patients admitted to hospital with an acute exacerba-
tion of COPD meet the Universal Definition for Myocardial Infarc-
tion,22 but it is unclear whether this represents type 2 AMI triggered
by the exacerbation or type 2 AMI misdiagnosed as the exacerba-
tion. At least 33% of patients admitted with COPD in whom there
is evidence of prior AMI have no recorded cardiac diagnosis and the
proportion is even higher among women with COPD.23 The erro-
neous attribution of symptoms to COPD rather than AMI may delay
diagnosis and the delivery of reperfusion therapy with adverse
consequences for infarct size and prognosis. In an analysis of over
300 000 first AMIs in the UK, Rothnie et al.18 found that COPD pa-
tients presenting with STEMI were more likely to have an initial in-
correct diagnosis and a longer median time to reperfusion
compared with patients without COPD [153 min (IQR, 74–
706 min) vs. 109 min (IQR, 50–260 min)]. The difference persisted
after adjustment for age, sex, and co-morbidities and was only ap-
parent in those COPD patients in whom diagnosis was delayed.
Recent studies conducted in Sweden and the UK have shown that
patients with COPD are less likely than patients without COPD to
receive primary percutaneous intervention (pPCI) or other reperfu-
sion strategies after a STEMI,16,18 confirming earlier US studies.17,21
A more recent US study, however, found no difference in rates of
pPCI between patients with and without COPD, suggesting a change
in practice and emphasizing the importance of observational data for
identifying inequalities in patient management.20
NSTEMI guidelines recommend in-hospital cardiac catheterization
within 72 h for patients with a ≥3% predicted risk of death at
6 months.24,25 Percutaneous intervention, as indicated, improves out-
comes, patients at highest risk having most to gain from the interven-
tion.26,27 Several studies have shown that patients with COPD who
present with NSTEMI are less likely to receive in-hospital angiography
compared with patients without COPD, despite being at higher
risk.16–18,20,21 A potential explanation for this difference is that COPD
patients are older and more likely to be deemed sicker or frailer than
non-COPD patients, and not appropriate for more aggressive interven-
tion. However, when comparisons are made after exclusion of patients
inappropriate for angiography due, for example, to advanced cancer
or dementia, findings of under-treatment are unchanged and rates of
angiography remain lower in patients with than without COPD.18
Figure 1 Diagram representing how inflammation in chronic obstructive pulmonary disease may ‘spill over’ into the systemic circulation and
increase the risk of several diseases including cardiovascular disease. Original image from Barnes.9
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Under-treatment of patients with COPD presenting with AMI ex-
tends beyond the acute phase. Contemporary guideline recommen-
dations, based on randomized clinical trials, are for secondary
prevention treatment with a b-blocker, an ACE inhibitor or angioten-
sin receptor blocker, a statin, and dual antiplatelet therapy (aspirin in-
definitely and P2Y12 receptor antagonist for 1 year) for all patients with
AMI unless there are clear contraindications.24,25 It has been thewidely
held belief that COPD contraindicates treatment with b-blockers be-
cause of the potential risk of bronchospasm caused by unopposed ac-
tivation of a1 adrenergic receptors that result in smooth muscle
constriction. However, many studies have shown that cardioselective
b-blockers that are primarily active at cardiac b1 receptors, not bron-
chial b2 receptors, are not associated with a change in FEV1 or an in-
crease in exacerbations of COPD.28 Despite this, b-blockers continue
to be underused in patients with COPD who are less likely than pa-
tients without COPD to receive a prescription after AMI.16–18,21
The under-treatment of patients with COPD extends to other sec-
ondary prevention drugs, all of which, with the exception of P2Y12 re-
ceptor antagonists, tend to be prescribed less commonly in patients
with COPD, although the differences are less marked compared
with b-blockers.16–21 Findings from studies that have investigated dif-
ferences in treatment between COPD and non-COPD patients after
AMI are summarized in Table 1. Interestingly, differences in manage-
ment between COPD and non-COPD patients are not apparent in
all settings and appear to have changed over time. As previously men-
tioned, differences in rates of pPCI between patients with and without
COPD appear to have narrowed over time in the USA,20 where pre-
scription of b-blockers to patients with COPD has increased unlike in
Europe.16–18 These differences between countries suggest two things:
that differences in treatment between COPD and non-COPD patients
do represent under-treatment, and that change is possible.
Outcomes after myocardial
infarction in people with chronic
obstructive pulmonary disease
All-cause mortality
Studies in a variety of settings have demonstrated an increased risk of
death during follow-up after AMI for patients with COPD, but whether
this applies to in-hospital mortality is less certain, some studies report-
ing increased mortality16,17,20,21,29–31 and others finding no differ-
ence15,32 compared with patients without COPD. The evidence has
now been appraised in a systematic review and meta-analysis,11 which
concluded that after pooling maximally adjusted estimates from several
studies, there is only weak evidence for a difference in in-hospital mor-
tality for patients with COPD (OR 1.13, 95% CI 0.97–1.31) but strong
evidence for an increased risk of death during follow-up (HR 1.26, 95%
CI 1.13–1.40) (Figure 2). However, effects were heterogeneous be-
tween studies perhaps because of the international differences in treat-
ment of AMI between patients with and without COPD. If some of the
increased risk of death associated with COPD is due to these treat-
ment differences, this is likely to have contributed to the heteroge-
neous outcomes identified in the systematic review.
The effect of COPD on risk of death following AMI is modified by
mode of presentation, a recent UK study reporting that the adjusted
odds of in-hospital and 6-month mortality were higher for NSTEMI
[(OR 1.40, 95% CI 1.30–1.52) and (OR 1.63, 95% CI 1.56–1.70)]
compared with STEMI [(OR 1.27, 95% CI 1.16–1.39) and (OR 1.43,
95% CI 1.29–1.58)].18 Similar findings have been reported in a US
study.20 The effect of COPD on risk after AMI appears to be greater
in younger than in older patients (Figure 3), suggesting that the ‘excess’
risk of death, attributable to COPD, is clustered in younger patients.18
Dziewierz et al.30 made a similar observation, reporting that COPD
was associated with an increased mortality risk after AMI only in pa-
tients aged ,75. The increased AMI mortality estimates in studies
that have compared patients with and without COPD are likely to
be underestimates based on the atypical presentations that character-
ize these patients, a proportion of whom, no doubt, escape diagnosis
altogether. Further contribution to the underestimation of risk in
these patients is the absence of data on pre-hospital mortality, all ex-
isting studies being confined to patients admitted to hospital.
Other outcomes
Outcome analyses after AMI in patients with COPD show that the risk
of other endpoints, apart from mortality, may also be increased. This
applies particularly to heart failure both in the acute phase and after
discharge from hospital. Thus, Stefan et al.17 found that after adjusting
for confounders, people with COPD were more likely to experience
acute heart failure (OR 1.59, 95% CI 1.37–1.83), compared with pa-
tients without COPD, but not atrial fibrillation, cardiogenic shock, or
stroke. Similar findings have been reported in unadjusted analyses.15,20
Studies of longer-term complications of AMI in patients with COPD
confirm that the increased risk of heart failure compared with patients
without COPD extends to the chronic phase after discharge from
hospital, Andell et al. reporting a hazard ratio of 1.35 (95% CI 1.24–
1.47) during the first year.16 Findings were similar in another study
that included patients with heart failure or left ventricular systolic dys-
function, and reported a hazard ratio for admission with heart failure
of 1.19 (95% CI 1.05–1.34) among patients with COPD during the
first 3 years after AMI.33 In the same study, the hazard of sudden death
was also higher in patients with COPD (HR 1.26, 95% CI 1.03–1.53),
although whether this applies in less selected populations is unclear.
Certainly, there is no convincing evidence that patients with COPD
are at higher risk of recurrent AMI, stroke, angina, or major bleeds
compared with non-COPD patients.16,19,33
Are differences in recognition
and management associated with
differences in outcomes?
A key question that arises from the tendency of patients with COPD
to present atypically and receive under-treatment of AMI is the ex-
tent to which this might explain their adverse outcomes, particularly
their heightened risk of death and heart failure compared with pa-
tients without COPD.
The association of atypical presentation of AMI with adverse out-
comes has been previously reported.34,35 Patients who present
atypically are less likely to receive guideline-recommended reperfu-
sion therapy or invasive management and are less likely to receive
b-blockers, statins, or antiplatelet therapy on discharge from hos-
pital.35 The tendency of patients with COPD to present with atyp-
ical symptoms is, therefore, important because delayed diagnosis of
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Table 1 Summary of studies that investigated differences in treatment after myocardial infarction between chronic
obstructive pulmonary disease and non-chronic obstructive pulmonary disease patients
Study Design and setting Population Differences in management
Andell et al. 201416 Cohort study within the Swedish
SWEDEHEART registry between
2005 and 2010
Consecutive patients admitted to
Swedish coronary care units.
COPD diagnosis ascertained
through linkage to the Swedish
National Patient Registry
In-hospital management
Percutaneous coronary intervention
COPD: 37.7%
Non-COPD: 55.7%
P, 0.001
Coronary angiography
COPD: 72.5%
Non-COPD: 55.4%
P, 0.001
Discharge medicines
ACE inhibitors
COPD: 50.6%
Non-COPD: 55.5%
P, 0.001
Angiotensin receptor blockers
COPD: 12.6%
Non-COPD: 11.1%
P ¼ 0.001
Aspirin
COPD: 85.5%
Non-COPD: 90.1%
P, 0.001
b-Blockers
COPD: 77.7%
Non-COPD: 86.1%
P, 0.001
Statin
COPD: 68.4%
Non-COPD: 79.2%
P, 0.001
P2Y12 inhibitor
COPD: 62.5%
Non-COPD: 72.2%
P, 0.001
Bursi et al. 201021 Cohort study in Olmsted County, MN
from 1979 to 2007
3438 local residents in Olmsted
County. ICD-10 codes used to
ascertain COPD
In-hospital management
Reperfusion
COPD: 41%
Non-COPD: 52%
P, 0.01
Angiography in-hospital
COPD: 51%
Non-COPD: 59%
P, 0.01
Discharge medicines
ACE inhibitor
COPD: 37%
Non-COPD: 29%
P, 0.01
b-Blocker
COPD: 47%
Non-COPD: 61%
P, 0.01
Diuretic
COPD: 34%
Non-COPD: 23%
P, 0.01
Statin
COPD: 29%
Non-COPD: 30%
P ¼ 0.61
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Table 1 Continued
Study Design and setting Population Differences in management
Enriquez et al. 201320 Cross-sectional study of National
Cardiovascular Data Registry in the
USA between January 2008 and
December 2010
158 890 patients with an acute MI.
Chronic obstructive pulmonary
disease was ascertained from
history of COPD or were using
long-term inhaled or oral
b-agonists, inhaled
anti-inflammatory agents,
leukotriene receptor antagonists,
or inhaled steroids
STEMIs
In-hospital management
Primary percutaneous coronary intervention
COPD: 83.1%
Non-COPD: 85.4%
P, 0.001
Overall reperfusion
COPD:92.8%
Non-COPD: 94.3%
P, 0.001
Discharge medicines
Aspirin
COPD: 97.8%
Non-COPD: 98.7%
P, 0.001
b-Blocker
COPD: 89.4%
Non-COPD: 93.1%
P, 0.001
ACE inhibitor or angiotensin receptor blocker
COPD: 78.0%
Non-COPD: 78.4%
P ¼ ‘not statistically significant’
Statin
COPD: 92.9%
Non-COPD: 94.7%
P, 0.001
P2Y12 inhibitor
COPD: 79.6%
Non-COPD: 86.6%
P, 0.001
NSTEMIs
In-hospital management
Cardiac catheterization
COPD: 69.9%
Non-COPD:81.2%
P, 0.001
Percutaneous coronary intervention within
48 hours
COPD: 37.2%
Non-COPD 48.9%
P, 0.001
Discharge medicines
Aspirin
COPD: 95.9%
Non-COPD: 97.3
P, 0.001
b-Blocker
COPD: 85.5%
Non-COPD: 90.5%
P, 0.001
ACE inhibitor or angiotensin receptor blocker
COPD: 69.6%
Non-COPD: 69.6%
P ¼ ‘not statistically significant’
Statin
COPD: 85.9%
Non-COPD: 89.5%
P, 0.001
P2Y12 inhibitor
COPD: 65.5%
Non-COPD: 71.6%
P, 0.001
Continued
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Table 1 Continued
Study Design and setting Population Differences in management
Rothnie et al. 201518 All UK patients admitted to hospital in
the MINAP registry between 2003
and 2013
300 161 patients with a first MI STEMI
In-hospital management
Primary PCI
OR 0.87 (95% CI 0.83–0.92)a
Discharge medicines
Aspirin
OR 0.90 (95% CI 0.85–0.94)a
b-Blocker
OR 0.26 (95% CI 0.25–0.27)a
ACE inhibitor or angiotensin receptor blocker
OR 0.89 (95% CI 0.85–0.93)a
Statin
OR 0.91 (95% CI 0.86–0.95)a
P2Y12 inhibitor
OR 0.98 (95% CI 0.94–1.03)a
NSTEMI
In-hospital management
Angiography in-hospital
OR 0.69 (95% CI 0.66–0.71)a
Discharge medicines
Aspirin
OR 0.91 (95% CI 0.88–0.94)a
b-Blocker
OR 0.25 (95% CI 0.24–0.25)a
ACE inhibitor or angiotensin receptor blocker
OR 0.94 (95% CI 0.91–0.97)a
Statin
OR 0.93 (95% CI 0.90–0.96)a
P2Y12 inhibitor
OR 0.97 (95% CI 0.94–1.01)a
Salisbury et al. 200719 Cohort study in 19 centres in the USA
between 2003 and 2004
2481 MI patients in PREMIER study
restricted to patients discharged
alive after MI
In-hospital management
Cardiac catheterization
COPD: 45.7%
Non-COPD: 41.2%
P ¼ 0.094
Percutaneous coronary intervention
COPD: 50.9%
Non-COPD: 62.9%
P, 0.001
Discharge medicines
Aspirin
COPD: 87.8%
Non-COPD: 94.5%
P, 0.001
b-Blocker
COPD: 86.2%
Non-COPD: 92.6%
P, 0.001
Stefan et al. 201217 Cohort study of patients hospitalized
with acute MI at greater
Worcester, MA between 1997 and
2007
6290 patients hospitalized with acute
MI in greater Worcester, MA
medical centres
In-hospital management
Cardiac catheterization
OR 0.56 (95% CI 0.48–0.65)b
Percutaneous coronary intervention
OR 0.64 (95% CI 0.54–0.77)b
Discharge medicines
b-Blocker
OR 0.44 (95% CI 0.35–0.50)b
Anticoagulant
OR 0.81 (95% CI 0.69–0.95)b
Statin
OR 0.70 (95% CI 0.60–0.82)b
Calcium channel blocker
OR 1.31 (95% CI 1.13–1.52)b
aAll ORs compared COPD with non-COPD patients and are adjusted for age, sex, smoking status, and co-morbidities.
bORs compare COPD with non-COPD patients and are adjusted for age, sex, year, cardiovascular disease history, renal failure, length of stay, and type of MI (STEMI or NSTEMI).
K.J. Rothnie and J.K. Quint86
Downloaded from https://academic.oup.com/ehjqcco/article-abstract/2/2/81/1748487
by London School of Hygiene & Tropical Medicine user
on 27 February 2018
AMI and its under-treatment with reperfusion therapy and second-
ary prevention drugs has now been shown to explain some of the
excess mortality for patients with COPD.18 Similar findings have
been reported by Andell et al.16 who found that hazard ratios for
mortality in COPD patients fell from 1.32 (95% CI 1.24–1.40) to
1.14 (95% CI 1.07–1.21) following adjustment for in-hospital and
discharge treatment. These findings point strongly to delayed diag-
nosis of AMI and its under-treatment as being important mediators
of the adverse outcomes for patients with COPD. They also suggest
that differences in treatment between countries may be a plausible
reason for heterogeneity in the effects of COPD on risk of death.
In considering delayed diagnosis of AMI and its under-treatment
as causes of excess mortality, potential direct effects of COPD
should not be overlooked (Figure 4). Chronic obstructive pulmonary
disease severity, defined by degree of airflow obstruction, appears
to be a risk factor for AMI,36 but lung function data are unavailable
in national AMI registries and it is unclear if it is also a risk factor for
outcomes after AMI. Exacerbations of COPD, however, and the as-
sociated systemic inflammation, are important drivers of mortal-
ity,11,37–39 but whether ‘frequent exacerbators’ are at heightened
risk of death after AMI is uncertain. There is greater certainty about
the risks associated with smoking that is often responsible for
COPD and is also a major risk factor for death and recurrent cor-
onary events after AMI.40 Indeed, quitting smoking after AMI is one
of the most effective preventive strategies, but in heavily dependent
COPD patients may be hard to achieve. Smoking cessation pharma-
cotherapy is underused, and although it may be less effective after
AMI,41,42 the excess mortality in patients with COPD identifies
them as a group that needs targeting.
The under-treatment of AMI in patients with COPD is important
because it is potentially modifiable, and provides a means of narrow-
ing the mortality gap between patients without COPD. Although
under-treatment can be identified across the management spec-
trum, it is b-blockers that stand out as the drugs that clinicians often
avoid for fear of exacerbating airways obstruction, and this despite
there being clear evidence that cardio-selective agents are safe for
COPD patients with AMI and also effective for secondary preven-
tion. Thus, Quint et al.43 conducted a propensity matched cohort
study in COPD patients with AMI and showed that patients started
on a b-blocker during hospital admission had significantly better
Figure 2 Long-term risk of death following MI comparing chronic obstructive pulmonary disease with non-chronic obstructive pulmonary
disease patients. Original image from Rothnie et al.11
Figure 3 Effect of chronic obstructive pulmonary disease on risk of death 6 months after myocardial infarction split by age group. Adapted from
data presented in Rothnie et al.18
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survival than patients not prescribed a b-blocker (HR 0.50, 95% CI
0.36–0.69). Similar results have been reported for a heart failure
population with AMI33 in which COPD did not appear to modify
the effect of b-blockers on mortality. The continuing reluctance
of clinicians to prescribe b-blockers to COPD patients needs
addressing because it may drive much of the increased risk of heart
failure and death in the months and years following AMI.
Other potential contributors to the risk management paradox44
that characterizes AMI patients with COPD include the poor per-
formance of risk algorithms and therapeutic nihilism. Thus, the
GRACE score appears to perform less well in patients with
COPD, but whether this makes a significant contribution to under-
treatment seems unlikely because COPD patients with the same
GRACE score as non-COPD patients remain less likely to receive
guideline-recommended investigation and treatment.45 Potentially
more important is therapeutic nihilism whereby COPD patients
are seen as too old and frail to make interventional management
and secondary prevention worthwhile, even though cardiovascular
disease is a leading cause of death in patients with COPD and many
of the excess deaths are in younger patients.
Conclusions
Chronic obstructive pulmonary disease increases the risk of heart
failure and death after AMI, particularly in the months after discharge
from hospital. Effects are greater in younger patients and those with
NSTEMI. Although direct effects of COPD likely contribute to the
increased risk, delays in diagnosis and under-treatment are also im-
portant. It is the under-treatment of these patients, particularly
with b-blockers, that provides the most modifiable target for redu-
cing mortality. Further research is needed to investigate the extent
and impact of missed AMI diagnosis in patients with COPD. Re-
searchers should also focus on investigating how AMI risk scores
function in COPD and how they should be used to guide treatment.
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